HK Stock Market Move | UBTECH ROBOTICS (09880) opened nearly 3% higher and established a long-term strategic partnership with Foxconn on human-like Siasun Robot & Automation in the field of intelligent manufacturing.
UBuy (09880) opened nearly 3% higher, as of the time of writing, it has increased by 2.94% to 49 Hong Kong dollars, with a trading volume of 7.9184 million Hong Kong dollars.
UBTECH ROBOTICS (09880) opened nearly 3% higher, up 2.94% as of the time of writing, at 49 Hong Kong dollars, with a trading volume of 7.9184 million Hong Kong dollars.
On the news front, on January 15, Foxconn and UBTECH ROBOTICS announced that they would establish a comprehensive and long-term strategic cooperation relationship on the application of humanoid Siasun Robot&Automation in the field of smart manufacturing. By conducting testing and verification of humanoid Siasun Robot&Automation in real manufacturing scenarios and promoting technological innovation, they aim to actively promote the practical application of UBTECH ROBOTICS humanoid Siasun Robot&Automation in Foxconn's intelligent manufacturing scenarios.
According to the agreement, the senior management of both parties will communicate regularly, coordinate, solve related cooperation matters, and accelerate the industrial chain construction and commercialization of humanoid Siasun Robot&Automation. The global market for humanoid Siasun Robot&Automation is becoming increasingly popular, with many institutions predicting that humanoid Siasun Robot&Automation will enter the mass production year by 2025. Currently, UBTECH ROBOTICS's industrial humanoid Siasun Robot&Automation Walker S1 has conducted a two-month training program at Foxconn's factory in Longhua, Shenzhen, successfully verifying the feasibility of humanoid Siasun Robot&Automation in logistics scenarios. In the second phase, UBTECH ROBOTICS's industrial humanoid Siasun Robot&Automation will enter Foxconn's training program at its car factory in Zhengzhou, Henan.
Related Articles

Shanghai Pharmaceuticals Holding (601607.SH): Telmisartan tablets obtain approval number from the US FDA

On November 6th, GREENTOWN SER (02869) spent approximately 965,000 Hong Kong dollars to repurchase 212,000 shares.

Nanjing Vazyme Biotech (688105.SH) subsidiary obtains two medical device registration certificates.
Shanghai Pharmaceuticals Holding (601607.SH): Telmisartan tablets obtain approval number from the US FDA

On November 6th, GREENTOWN SER (02869) spent approximately 965,000 Hong Kong dollars to repurchase 212,000 shares.

Nanjing Vazyme Biotech (688105.SH) subsidiary obtains two medical device registration certificates.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


